ML&P Blog: Our insight into current issues

Medicines Law & Policy periodically will post timely analysis and insight into current events related to intellectual property and innovation policy as they impact on access to medicines. These posts are listed below. We also have a newsletter for those interested in being notified when new articles are posted.

Latest Blog Posts

World Trade Organization Members Embark on Review of the TRIPS Agreement

The World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council will meet on 10-11 July. On the agenda is the review...

MSF’s Access Campaign is an invaluable actor in global health; shutting it down is short-sighted.

On 20 June, STAT News reported that Médecins Sans Frontières (MSF) is closing down their Access Campaign, effective as of 31 December 2024. It...

The new IP strategy of war-torn Ukraine should prioritise public health and national security

Russia’s full-scale assault on Ukraine continues for the third year. The Russian occupation forces have already killed tens of thousands of civilians, including children. They have...

Continuing to ignore the problem of the know-how gap won’t make it go away.

The Covid-19 pandemic was a wake-up call for a variety of issues in access to medicines, one of which was finding a solution to...

Pharmaceutical Accountability Foundation meets AbbVie in court, looking to advance its pricing case

“The value of a human life is infinite, but unfortunately our healthcare budget is not,” said former Dutch Health Minister Bruno Bruins, quoted by...

Pressure from European countries related to the use of TRIPS Flexibilities 

The draft text of the World Health Organization pandemic accord reaffirms countries' rights to use to the full the flexibilities contained in the World...

The last mile: A few suggestions for the WHO Pandemic Agreement’s last two weeks of talks 

This technical briefing note is also available as a PDF here. On 16 April, the Bureau of the Intergovernmental Negotiating Body (INB) to draft and...

US Authorisation of Non-Voluntary Use of Patents frequently used for health technologies

During the Covid-19 pandemic, the United States prioritised the rapid development of products needed to combat the health crisis.  Rapid product development was pursued...

European Parliament’s amendments make the Regulation for EU-wide compulsory licensing difficult to use and need to be rolled back

European Parliament legislative resolution of 13 March 2024, on the proposal for a regulation of the European Parliament and of the Council on compulsory...

Worldwide licensing of pandemic technologies is already current practice. The Pandemic Accord should protect it.

The negotiations for a WHO pandemic accord are still in full swing this week. Talks are taking place behind closed doors, but it is...

Newsletter

Never miss a post! Sign up for ML&P's newsletter.

Posts by topic

Year-End Wrap-Ups